Suzette Bielinski, Ph.D.

Study Chair

Pharmacogenomics: RIGHT 10K Study

Mayo Clinic is collaborating with the Baylor College of Medicine to sequence 77 pharmacogenes from Mayo Clinic Biobank samples from 10,000 patients who receive all of their health care at Mayo Clinic in Rochester, Minnesota. Results from a subset of the 77 pharmacogenes will be placed into the electronic health record (EHR) and an interpretive report will be placed into the patient's medical record.

With the specific genotypes loaded into the EHR, Mayo can not only improve their health care by utilizing already-installed clinical decision support alerts for 19 different drug-gene pairs, but can also systematically evaluate the clinical and fiscal impact of those alerts. The study team can also do retrospective analysis of EHR data determine how the presence of genetic information might have altered patient outcomes.

We are incorporating patient/provider education and bioethics activities into the RIGHT 10K study and we also know that a subset of the 10K patients will have variants of unknown significance in these important pharmacogenes. The RIGHT 10K study will include functional studies to identify those variants.


This study has already recruited all eligible participants who were:

  • Enrolled in the Mayo Clinic Biobank
  • Residents of Minnesota's Olmsted, Dodge, Goodhue, Wabasha, Winona, Mower and Fillmore counties
  • Assigned to receive primary care from a clinician in one of Mayo's Internal Medicine Clinics (For example, Primary Care Internal Medicine, Family Medicine)
  • Able to provide informed consent


Patients, referring physicians and research collaborators can obtain information about the RIGHT protocol by calling 855-678-0741.

You can also contact the Center for Individualized Medicine for information on other studies and trials.

Support this study

Support for this study comes from the Mayo Clinic Center for Individualized Medicine, a grant from Roche, and grateful Mayo Clinic patients.

Support individualized medicine